News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
whatever the reason! 
We will freeze, imo! 
currently its only a shell play!
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
840
|
|
Created
|
03/09/07
|
Type
|
Free
|
| Moderators | |||
http://finance.yahoo.com/q/h?s=ABPH.PK
BioScanIR® The most advanced infrared sensors used in Space are now part of the most advanced biomedical infrared imaging system on the planet - the BioScanIR® System:
Detects dynamic changes in blood perfusion in tissue and organs by sensing minute changes in thermal photon flux
Completely non-invasive—no contrast agents, no ionizing radiation used
Fast results—scans in 20 seconds and data reports available in minutes
Low cost—up to 80% less than other functional imaging modalities FDA-Cleared, UL-Certified and CE-Marked
The BioScanIR System is an infrared-based functional imaging system that detects minute changes in blood perfusion through the capture of passively-emitted infrared radiation that is produced by tissue. Through the analysis of this captured radiation, the system can help physicians and researchers differentiate between normal and abnormal tissue. In this fashion, the BioScanIR System can detect diseases and conditions that affect the perfusion or reperfusion of blood in tissue and organs.
The BioScanIR System is totally non-invasive, and does not contact the patient in any way. It uses no radiation, and requires no contrast agent. It can be used by non-imaging specialists, and can be used in a non-sterile, office environment. The BioScanIR System has multiple clinical applications including:
Monitoring response to cancer drug therapy.
Monitoring intervention in diabetic driven peripheral vascular disease.
Identifying perforator vessels during pre-surgical planning, and assessing post-operative perfusion of pedicle flaps following reconstructive surgery (i.e. of the breast).
Mapping of functional cortex in patients undergoing tumor surgery.
Determining cardiac bypass graft patency and perfusion of the myocardium in cardiac surgery.
The BioScanIR System can be used adjunctively with more expensive modalities such as CT, MRI, functional MRI and PET imaging.
To learn more about specific clinical use, visit our Applications Section
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
by Ronald C. Trahan
A PREVIEW OF EARLY-STAGE
MEDICAL TECHNOLOGY COMPANIES
The latest Filings and News:
December 17th 2007..... Big News.... Please Read
http://biz.yahoo.com/bw/071217/20071217006052.html?.v=1
MISC NEWS:
Frost & Sullivan's 2005 Medical Imaging in Cancer & Vascular Disease Diagnostics Product Leadership of the Year Award
http://medgadget.com/archives/2005/03/the_bioscanir_s.html
OmniCorder Technologies Installs BioScanIR System at Leading German Cancer Center
http://findarticles.com/p/articles/mi_m0EIN/is_2004_Feb_18/ai_113374281
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
http://www.medtechinsight.com/advertorials/starwars.pdf
12-20-07 The following info was furnished by Mgland. He spoke directly to the TA
OS. The Transparency we embrace. Company has been very prudent here with the share structure but does have to pay the bill with things coming to fruition.
52 MILLION @ .0011 GIVES A MKT CAP OF $57,200.
OS by date (2007)
On 5/30 it was 38 million
on 6/22 39 million
7/10 40 million
9/25 unchanged
11/23 unchanged
11/30 42 million
12/19 52 million
(2009)
2/26 58 million (confirmed by FatFinger6)
It ran from pennies to $9 in 2004
Advanced BioPhotonics, Inc., a development stage company, engages in the development and commercialization of digital imaging technology for the diagnosis and management of various diseases, including cancer and vascular diseases in the United States. Its principal product includes BioScanIR system, which detects diseases that affect the perfusion or reperfusion of blood in tissues and organs. The BioScanIR system assists physicians and researchers in differentiating between normal and abnormal tissues by detecting small changes in perfusion. Advanced BioPhotonics, formerly known as OmniCorder Technologies, Inc., was founded in 1997 and changed its name to Advanced BioPhotonics, Inc. in 2005. The company is headquartered in Bohemia, New York.
Planned Clinical Trials in 2007.
· Pigmented Lesions of the Skin assessment (Melanoma). Melanoma detection and assessment represents a large clinical problem and a disease state where the BioScanIR® system may readily measure and assess the primary photonic emissions of skin tumors. In July 2007, we began a pilot research trial at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School. The first results for this trial are anticipated to be available in late November 2007. ·
Adjunctive screening and detection of breast cancer. The use of the BioScanIR® system as an adjunctive technique in breast cancer detection in certain age categories still holds great promise. This application may be particularly useful in younger women (under 50 years of age) with dense breasts who are at increased risk for breast cancer. We will continue to support the current work being done at the State University of New York Stony Brook in this area. First results should be available in late 2007.
We intend to concentrate our efforts and pursue clinical trials in the above noted applications provided that we have sufficient funds to do so. Previously, we had reported that we had also intended to organize a clinical trial to test the assessment of peripheral perfusion. The assessment of peripheral perfusion after tourniquet stress is a non invasive method of measuring peripheral outflow as a measure of systemic vascular disease. The current methods employ ultrasound techniques over which we may have significant benefits. After further investigation, we have decided to focus our limited assets on pigmented lesions of the skin assessment (Melanoma) and adjunctive screening and detection of breast cancer. As of November 1, 2007, we had two fully functional prototype or commercial units installed in various U.S. medical institutions for testing and evaluation.
Gallery View 4: (Full Sto, MACD, Aroon8)
